ArticleInternational journal of nephrology2026
Comparative Performance of the ANCLA Risk Score and Established Prognostic Models for Predicting ESKD in ANCA-Associated Glomerulonephritis: A Latin American Cohort.
Article in International journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prognostic tools for kidney outcomes in ANCA-associated vasculitis (AAV) were developed mainly in European and North American populations, and their performance in Hispanic populations remains less well characterized. ANCA in Latin America (ANCLA) was previously developed and internally validated in a Colombian cohort to predict end-stage kidney disease (ESKD). Objective: To compare the prognostic performance of ANCLA with the Berden classification, Renal Risk Score (RRS), Mayo Clinic Chronicity Score (MCCS), and the ANCA Kidney Risk Score (AKRiS) for ESKD prediction in ANCA-associated glomerulonephritis. Methods: This secondary comparative analysis used the previously described ANCLA derivation cohort of 164 adults with biopsy-proven pauci-immune necrotizing and/or crescentic glomerulonephritis treated from 2011 to 2024 at a tertiary referral center in Colombia. The five prognostic systems were evaluated in the same population using Kaplan-Meier analyses, Harrell's C-index, and 1- and 2-year ROC analyses. Pairwise AUC differences between ANCLA and each comparator were formally assessed. Results: During a median follow-up of 12.9 months, 63 patients (38.4%) progressed to ESKD. ANCLA showed the most favorable overall discrimination (C-index 0.801; AUC 0.890 at 1 year and 0.896 at 2 years), followed by AKRiS (C-index 0.760) and RRS (0.749); MCCS (0.673) and Berden (0.640) showed lower discrimination. ANCLA had significantly higher AUCs than MCCS and Berden at both horizons, whereas differences versus AKRiS and RRS were smaller. ESKD occurred in 7.3% of the ANCLA low-risk group and 82.5% of the very-high-risk group. Conclusion: In this high-risk, predominantly Hispanic Latin American cohort, ANCLA showed the most favorable short-term discrimination, while AKRiS and RRS also performed well. Independent external validation remains necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.